Assessment of the effect of pretreatment with neoadjuvant therapy on primary breast cancer

British Journal of Cancer

Volumn 73, Issue 6, 1996, Pages 758-762

  Gazet, J C ^a,b   Coombes, R C ^a   Ford, H T ^a   Griffin, M ^a   Corbishley, C ^a   Makinde, V ^a   Lowndes, S ^a   Quilliam, J ^a   Sutcliffe, R ^a  

^a ST GEORGE S HOSPITAL   (United Kingdom)

^b NONE   (United Kingdom)

Author keywords

Neoadjuvant therapy; Pretreatment; Primary breast cancer

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC ANTIBIOTIC; ESTROGEN RECEPTOR; FOLIC ACID ANTAGONIST; FORMESTANE; GONADORELIN; GOSERELIN; LEUPRORELIN; METHOTREXATE; MITOMYCIN C; MITOXANTRONE; ANDROSTENEDIONE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; DRUG DERIVATIVE; MITOMYCIN; MMM PROTOCOL 2;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER INVASION; CLINICAL TRIAL; FEMALE; HUMAN; HUMAN TISSUE; INTRAMUSCULAR DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; ADJUVANT CHEMOTHERAPY; ADULT; AGED; BREAST TUMOR; CHEMISTRY; COMPARATIVE STUDY; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; NEOPLASM;

ADULT; AGED; ANDROSTENEDIONE; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; FEMALE; GOSERELIN; HUMANS; IMMUNOHISTOCHEMISTRY; METHOTREXATE; MIDDLE AGED; MITOMYCIN; MITOXANTRONE; NEOPLASMS, HORMONE-DEPENDENT; RECEPTORS, ESTROGEN;

EID: 0029664993     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.132     Document Type: Article

References (29)

1. ANDERSON EDC, FORREST APM, HAWKINS RA, ANDERSON TJ, LEONARD RC AND CHETTY V. (1991). Primary systemic therapy for operable breast cancer. Br. J. Cancer, 63, 561-566.
2. BONADONNA G, VERONESI U, BRAMBILLA C, FERRARI L, LUINI A, GRECO M, BARTOLI C, COOPMANS DEYOLDI G, ZUCALI R AND RILKE F. (1990). Primary chemotherapy to avoid mastectomy in tumours with diameters of three centimetres or more. J. Natl Cancer Inst., 82 (19), 1539-1545.
3. COOMBES RC, POWLES T AND GAZET J-C. (1980). Assessment of biochemical tests to screen for metastases in patients with breast cancer. Lancet, 1, 296-298.
4. COOMBES RC, GOSS P, DOWSETT M, GAZET J-C, BRODIE AMH. (1984). 4-Hydroxyandrostenedione in treatment of postmenopausal patients with advanced breast cancer. Lancet, 1, 1237-1239.
5. COBISHLEY C, GRIFFIN M, GAZET J-C, COOMBES R-C AND FORD HT. (1996). The pathological criteria for the assessment of breast tumour response to neoadjuvant therapy (in press).
6. CRIGHTON IL, DOWSETT M, LAL A, MAN A AND SMITH IE. (1989). Use of luteinising hormone-releasing hormone agonist (leuprorclin) in advanced postmenopausal breast cancer: clinical and endocrine effects. Br. J. Cancer, 60, 644-648.
7. CUNNINGHAM D, POWLES TJ, DOWSETT M, HUTCHISON G, BRODIE AMH, GAZET J-C AND COOMBES RC. (1987). Oral 4-hydroxyandrostenedione, a new endocrine treatment for disseminated breast cancer. Cancer Chemo. Pharmacol., 20, 253-255.
8. DELENA M, VARINI M, ZUCALI R, ROVINI D, VIGANOTTI G, VALAGUSSA P, VERONESSI U, BONADONNA G. (1981). Multimodal treatment for locally advanced breast cancer: results of chemotherapy-radiotherapy versus chemotherapy-surgery. Cancer Clin. Trials, 4, 229-236.
9. DIXON AR, ROBERTSON JRF, JACKSON L, NICHOLSON RI, WALKER KJ AND BLAMEY RW. (1990). Goserelin (Zoladex) in premenopausal advanced breast cancer: duration of response and survival. Br. J. Cancer, 62, 868-870.
10. DOWSETT M, MEHTA A, MANSI J AND SMITH IE. (1990). A dose-comparative endocrine clinical study of leuprorelin in premenopausal breast cancer patients. Br. J. Cancer, 62, 834-837.
11. FORREST APM, LEVACK PA, CHETTY U, HAWKINS RA, MILLER WR, SMYTH JF AND ANDERSON TJ. (1986). A human tumour model. Lancet, 2, 840-842.
12. GAZET J-C, FORD HT AND COOMBES RC. (1991). Randomised trial of chemotherapy versus endocrine therapy in patients presenting with locally advanced breast cancer (a pilot study). Br. J. Cancer, 63, 279-282.
13. GAZET JC, FORD HT, BLAND JM, SUTCLIFFE R, QUILLIAM J AND LOWNDES S. (1994). Prospective randomised trial of tamoxifen versus surgery in elderly patients with breast cancer. Eur. J. Surg. Oncol., 20, 207-214.
14. GOSS PE, POWLES TJ, DOWSETT M, HUTCHISON G, BRODIE AMH, GAZET J-C AND COOMBES RC. (1986). Treatment of advanced postmenopausal breast cancer with an aromatase inhibitor, 4-Hydroxyandrost-enedione: phase II report. Cancer Res., 46, 4823-4826.
15. HARRIS AL, CARMICHAEL J, CANTWELL BMJ AND DOWSETT M, (1989). Zoladex: endocrine and therapeutic effects in post-menopausal breast cancer. Br. J. Cancer, 59, 97-99.
16. HORTOBAGYI G, SINGLETARY E, MCNEESE M, FRYE D, HOLMES F, AMES F, THERIAULT RM AND BUZDAR A. (1991). Breast conservation after neoadjuvant chemotherapy (NACT) for primary breast cancer (BC). (Meeting abstract). Proc. Am. Soc. Clin. Oncol., 10, A95.
17. IVESON TJ, TALBOT DC, WALSH G, MCKINNA JA AND SMITH IE. (1991). Primary medical treatment for breast cancer (Meeting Abstract). Br. J. Cancer, 63, (suppl. 13), 10.
18. JODRELL DI, SMITH IE, MANSI JL, PEARSON MC, WALSH G, ASHLEY S, SINNETT HD AND MCKINNA JA. (1991). A randomised comparative trial of mitozantrone/methotrexate/ mitomycin C (MMM) and cyclophosphamide/methotrexate/ 5FU (CMF) in the treatment of advanced breast cancer. Br. J. Cancer, 63, 794-798.
19. NICHOLSON RI, WALKER KJ, TURKES A, DYAS J, PLOWMAN PN, WILLIAMS M AND BLAMEY RW. (1985). Endocrinological and clinical aspects of LHRH action (ICI118630) in hormone dependent breast cancer. J. Steroid Biochem., 23, 843.
20. PERLOFF M, LESNICK GJ, KORZUN A, CHU F, HOLLAND JF, THIRLWELL MP, ELLISON RR, CAREY RW, LEON L, WEINBERG U, RICE MA AND WOOD WC. (1988). Combination chemotherapy (CAFVP) with mastectomy or radiotherapy for Stage III breast carcinoma: a CALGB study. J. Clin. Oncol., 6, 261-269.
21. PLOWMAN PN, NICHOLSON RI AND WALKER KJ. (1986). Remission of postmenopausal breast cancer during treatment with the luteinising hormone releasing hormone agonist ICI 118630. Br. J. Cancer, 54, 903-909.
22. POWLES TJ, JONES AL, JUDSON IR, HARDY JR AND ASHLEY SE. (1991). A randomised trial comparing combination chemotherapy using mitomycin C, mitozantrone and methotrexate (3M) with vincristine, anthracycline and cyclophosphamide (VAC) in advanced breast cancer. Br. J. Cancer, 64, 406-410.
23. RAGAZ J, MANJI M, KUUSK U, PLENDERLEITH IH, BASCO V, BAIRD R, KNOWLING M, REBBECK M, OLIVOTTO P AND WORTH A. (1992). Is it safe to leave Stage III breast cancer without mastectomy (M) for 6-7 months while preoperative (neoadjuvant) therapy is received? Comparison of preoperative vs postoperative therapy and correlation of pathological lymph node status with mortality rate. (Meeting abstract). Proc. Anns. Meet. Am. Assoc. Cancer Res., 33, A1291.
24. RUBENS RD. (1992). The management of locally advanced breast cancer. Br. J. Cancer, 65, 145-147.
25. SHAW D, GIVEN-WILSON R AND GAZET J-C. Correlation of variations in tumour size as measured clinically and radiologically following neoadjuvant treatment for primary breast cancer. (in press).
26. SINGLETARY SE, MCNEESE MD AND HORTOBAGYI GN. (1992). Feasibility of breast conservation surgery after induction chemotherapy for locally advanced breast carcinoma. Cancer, 69 (11), 2849-2852.
27. STEIN RC, DOWSETT M, HEDLLY A, DAVENPORT J, GAZET J-C, FORD HT AND COOMBES RC. (1990). Treatment of advanced breast cancer in post-menopausal women with 4-Hydroxyandrostenedione. Cancer Chemo. Pharmacol., 26, 75-78.
28. SMITH IE, JONES AL, O'BRIEN MER, MCKINNA JA, SACKS N AND BAUM M. (1993). Primary medical (neo-adjuvant) chemotherapy for operable breast cancer. Eur. J. Cancer, 29A, 1796-1799.
29. SWAIN SL, SORACE RA, BAGLEY SC, DANFORTH DN, BADER J, WESLEY MN, STEINBERG SM AND LIPPMAN ME. (1987). Neoadjuvant chemotherapy in the combined modality approach of locally advanced non-metastatic breast cancer. Cancer Res., 47, 3889-3894.